Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04467840 · ClinicalTrials.gov registry record · Phase 2
Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
A Phase 2 study, sponsored by RedHill Biopharma Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 475
- Enrollment target
NCT04467840 is a Phase 2 study that has completed, run by RedHill Biopharma Limited. The registered enrollment target is 475 participants.
The verdict
NCT04467840, a Phase 2 study, has completed, sponsored by RedHill Biopharma Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 475 participants
- Enrollment target
Study Summary
A phase 2/3 multi-center randomized, double-blind, parallel arm, placebo- controlled study in Adult Subjects Hospitalized with Severe SARS-CoV-2 Positive Pneumonia to determine the potential of opaganib to improve and/or stabilize the clinical status of the patient.
Interventions
- DRUG Placebo
- DRUG Opaganib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 475 participants |
| Start Date | 2020-08-21 |
| Est. Completion | 2021-07-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04467840
The ClinicalTrials.gov registry entry for NCT04467840 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 475 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RedHill Biopharma Limited, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04467840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04467840 about?
NCT04467840 is a clinical study titled "Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia". A phase 2/3 multi-center randomized, double-blind, parallel arm, placebo- controlled study in Adult Subjects Hospitalized with Severe SARS-CoV-2 Positive Pneumonia to determine the potential of opaganib to improve and/or stabilize the clinical status of the patient.
What is the current status of trial NCT04467840?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 475 participants. The study started on 2020-08-21. Estimated completion is 2021-07-18.
What interventions are being tested in trial NCT04467840?
The interventions under investigation include: Placebo (DRUG), Opaganib (DRUG).
Who is sponsoring clinical trial NCT04467840?
This trial is sponsored by RedHill Biopharma Limited, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.